INT213221

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.01
First Reported 2006
Last Reported 2006
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 8
Disease Relevance 5.83
Pain Relevance 0.46

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Golgi apparatus (ASAP2) plasma membrane (ASAP2) cytoplasm (ASAP2)
Anatomy Link Frequency
blood 1
heart 1
aortic valve 1
ASAP2 (Homo sapiens)
Pain Link Frequency Relevance Heat
fibrosis 16 87.96 High High
cva 72 87.76 High High
agonist 8 84.36 Quite High
nud 8 67.40 Quite High
headache 24 66.24 Quite High
tolerance 32 55.44 Quite High
Potency 8 51.28 Quite High
antagonist 8 12.16 Low Low
cytokine 8 10.80 Low Low
Inflammation 8 10.40 Low Low
Disease Link Frequency Relevance Heat
Pressure Volume 2 Under Development 32 99.06 Very High Very High Very High
Eisenmenger Complex 8 97.76 Very High Very High Very High
Heart Defects 24 96.44 Very High Very High Very High
Pulmonary Hypertension 656 96.08 Very High Very High Very High
Increased Venous Pressure Under Development 88 95.40 Very High Very High Very High
Hypersensitivity Pneumonitis 8 90.88 High High
Occupational Lung Diseases 8 89.48 High High
Systemic Sclerosis 8 89.04 High High
Pulmonary Fibrosis 16 87.96 High High
Thrombosis 48 87.76 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Inhaled NO, epoprostenol, and sildenafil all resulted in a significant decrease in mPAP and PVRI.
Negative_regulation (decrease) of mPAP
1) Confidence 0.01 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994020 Disease Relevance 1.10 Pain Relevance 0.07
Ghofrani and colleagues also studied 14 patients deteriorating on inhaled iloprost and found that the addition of sildenafil resulted in an increased 6 minute walk distance, decreased mPAP, decreased PVR, and improved functional class (Ghofrani et al 2003).
Negative_regulation (decreased) of mPAP
2) Confidence 0.01 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994020 Disease Relevance 0.45 Pain Relevance 0.04
In one, sildenafil decreased the mPAP from 58 to 29 mmHg and the PCWP from 32 to 18 mmHg after coronary bypass and mitral annuloplasty, improving systemic blood pressure.
Negative_regulation (decreased) of mPAP in blood
3) Confidence 0.01 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994020 Disease Relevance 0.59 Pain Relevance 0.04
Acute administration of a single oral dose of sildenafil causes a significant decrease in mPAP and PVR with minimal or no affect on mean arterial pressure (MAP) and improvement, or a trend towards improvement, in cardiac output.
Negative_regulation (decrease) of mPAP
4) Confidence 0.01 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994020 Disease Relevance 0.78 Pain Relevance 0.13
In the second, sildenafil was given intra-operatively during an aortic valve replacement for a mPAP of 90 mmHg accompanied by systemic hypotension despite epinephrine, milrinone resulting in a decrease in mPAP to 50 mmHg (Madden and Crerar-Gilbert 2005).
Negative_regulation (decrease) of mPAP in aortic valve associated with pressure volume 2 under development
5) Confidence 0.01 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994020 Disease Relevance 0.44 Pain Relevance 0.04
Right heart catheterization in 9 showed a significant reduction in mPAP from 60 to 50 mmHg and a decrease in pulmonary vascular resistance index from 15 to 12 wood units/m2 without a change in systemic hemodynamics.
Negative_regulation (reduction) of mPAP in heart
6) Confidence 0.01 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994020 Disease Relevance 0.92 Pain Relevance 0
Although sildenafil treatment decreased mPAP and PVRI, the study was stopped early due to worsening oxygenation and systemic hypotension associated with sildenafil (Stocker et al 2003).


Negative_regulation (decreased) of mPAP associated with pressure volume 2 under development
7) Confidence 0.01 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994020 Disease Relevance 0.80 Pain Relevance 0.12
Compared with placebo, there was a significant decrease in mPAP of 6.7 and 11.6 mmHg after the first dose of sildenafil and at 12 weeks, respectively.
Negative_regulation (decrease) of mPAP
8) Confidence 0.01 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994020 Disease Relevance 0.75 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox